Market Place
Sourcing Support
Regeneron Beats Quarterly Estimates On Strong Dupixent Demand
29 Apr 2026 //
REUTERS HEALTHCARE
Regeneron Announces Investor Conference Presentations
20 Apr 2026 //
GLOBENEWSWIRE
Telix And Regeneron Announce Strategic Radiopharma Collaboration
13 Apr 2026 //
GLOBENEWSWIRE
TriNetX & Regeneron to Share De-ID EHRs of 300M Patients
02 Apr 2026 //
PR NEWSWIRE
Regeneron Reports Q1 2026 Results, Hosts Earnings Call on Apr. 29
25 Mar 2026 //
GLOBENEWSWIRE
Regeneron Announces Investor Conference Presentation
05 Mar 2026 //
GLOBENEWSWIRE
Regeneron Announces Investor Conference Presentations
11 Feb 2026 //
GLOBENEWSWIRE
Regeneron Unveils 2025 Q4 & Full-Year Financial Results
30 Jan 2026 //
GLOBENEWSWIRE
Regeneron Faces Category Headwinds For Eye Disease Drug Eylea
30 Jan 2026 //
FIERCE PHARMA
BrightInsight Secures Multi-Million Investment For Ai Medication
20 Jan 2026 //
GLOBENEWSWIRE
Regeneron To Present Q4 2025 Financial Results, Host Conference
02 Jan 2026 //
GLOBENEWSWIRE
Regeneron To Invest $2B In New Saratoga Springs Production Plant
19 Nov 2025 //
FIERCE PHARMA
Regeneron Announces Investor Conference Presentations
03 Nov 2025 //
GLOBENEWSWIRE
Regeneron Unveils Q3 2025 Financial Results
28 Oct 2025 //
GLOBENEWSWIRE
Rising Stars: Kristen Raimondi On Creating New Hope For Patients
22 Oct 2025 //
FIERCE PHARMA
Regeneron, Sanofi Receive 1- To 2-Month Priority Review Vouchers
17 Oct 2025 //
FIERCE BIOTECH
Regeneron Shows Advances in Oncology Portfolio & Pipeline at ESMO
15 Oct 2025 //
GLOBENEWSWIRE
Regeneron To Present Q3 2025 Results, Host Conference On Oct 28
30 Sep 2025 //
GLOBENEWSWIRE
Regeneron Antibodies Triumph in Ph. 3 Cat, Pollen Allergy Trials
08 Sep 2025 //
FIERCE BIOTECH
Regeneron Reveals 2025 Creative Innovation Prize Winners
24 Jul 2025 //
GLOBENEWSWIRE
Regeneron to Report Q2 Results on August 1
26 Jun 2025 //
GLOBENEWSWIRE
Regeneron Launches Donation Matching Program with Charity
24 Jun 2025 //
GLOBENEWSWIRE
Regeneron to Highlight ASCO Advances with Libtayo Updates
01 May 2025 //
GLOBENEWSWIRE
Regeneron`s first-quarter results miss on lower Eylea demand
30 Apr 2025 //
REUTERS
Regeneron Announces Investor Conference Presentations
21 Apr 2025 //
GLOBENEWSWIRE
Regeneron to Report Q1 2025 Results, Host Conference on April 29
25 Mar 2025 //
GLOBENEWSWIRE
Regeneron Announces Investor Conference Presentations
11 Feb 2025 //
GLOBENEWSWIRE
Regeneron lays out bright future for newest blockbuster Libtayo
05 Feb 2025 //
FIERCE PHARMA
Regeneron Reports Q4 & Full Year 2024 Financial & Operating Results
04 Feb 2025 //
GLOBENEWSWIRE
Top 40 High School Scientists Compete At Regeneron Talent Search
23 Jan 2025 //
GLOBENEWSWIRE
Regeneron Highlights Clinical Pipeline Updates At Morgan Conference
13 Jan 2025 //
GLOBENEWSWIRE
Regeneron To Announce Q4 And FY24 Results On February 4, 2025
07 Jan 2025 //
GLOBENEWSWIRE
Regeneron forges ahead in factor XI despite field’s mixed results
20 Dec 2024 //
ENDPTS
New treatments needed in chronic hand eczema
19 Dec 2024 //
FIERCE PHARMA
Regeneron Announces Presentation at 43rd J.P. Morgan Health Conf.
17 Dec 2024 //
GLOBENEWSWIRE
Regeneron Highlights Blood Cancer Pipeline at ASH
13 Nov 2024 //
GLOBENEWSWIRE
Regeneron Reports Q3 2024 Financial and Operating Results
31 Oct 2024 //
GLOBENEWSWIRE
EYLEA HD® Injection Shows Gains In Diabetic Macular Edema.
18 Oct 2024 //
GLOBENEWSWIRE
Clearside`s CLS-AX excels in phase 2b trial, set for phase 3
10 Oct 2024 //
FIERCE PHARMA
Dupixent takes pharma DTC top spot in September
07 Oct 2024 //
FIERCE PHARMA
Regeneron To Report Third Quarter 2024 Financial Results
26 Sep 2024 //
GLOBENEWSWIRE
Demy-Colton`s BioFuture 2024 To Feature Regeneron, IBM, Ipsen, And VCs
11 Sep 2024 //
BUSINESSWIRE
Dupixent Phase 3 Trial Shows Improvement In Chronic Spontaneous Urticaria
11 Sep 2024 //
GLOBENEWSWIRE
Sonoma Biotherapeutics Receives $45M Regeneron Milestone
04 Sep 2024 //
CONTRACT PHARMA
ArsenalBio Snags Mega $325M Series C Round With Backing from Nvidia, Regeneron
04 Sep 2024 //
BIOSPACE
Regeneron takes on Sandoz over newly-approved Eylea copycat
29 Aug 2024 //
BLOOMBERG
Regeneron Gains European Nod For T-Cell Engager Odronextamab
27 Aug 2024 //
FIERCE PHARMA
Dupixent And Itepekimab Data At ERS Show Leadership In Respiratory Diseases
26 Aug 2024 //
GLOBENEWSWIRE
Regeneron Reports Second Quarter 2024 Financial and Operating Results
01 Aug 2024 //
GLOBENEWSWIRE
Regeneron Launches Eylea HD, Warns Of Linvoseltamab Manufacturing Issue
01 Aug 2024 //
FIERCE PHARMA
Regeneron Announces 2024 Prize For Creative Innovation Winners
31 Jul 2024 //
GLOBENEWSWIRE
Roche`s Vabysmo Climbs Despite Slowdown Amid Eylea Clash
25 Jul 2024 //
FIERCE PHARMA
Sanofi lifts 2024 profit forecast on strength in Dupixent, new products
25 Jul 2024 //
REUTERS
Court weighs what US must prove in Regeneron kickback case
23 Jul 2024 //
REUTERS
Docs embrace Takeda’s Eohilia, creating competition for Sanofi`s Dupixent
22 Jul 2024 //
FIERCE PHARMA
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
03 Jul 2024 //
PRESS RELEASE
Kuehn Law Urges Regeneron Investors To Contact Firm
02 Jul 2024 //
PR NEWSWIRE
Regeneron to Report Second Quarter 2024 Financial and Operating Results
27 Jun 2024 //
GLOBENEWSWIRE
Bayer`s pharmaceutical unit plans more managerial cuts in Europe, Asia
27 Jun 2024 //
REUTERS
US FDA approves Verona Pharma`s inhaled COPD therapy
27 Jun 2024 //
REUTERS
